ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox

An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload

NCT00171210 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia

NCT01709838 ·Status: COMPLETED ·Phase: PHASE4

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

NCT00110266 ·Status: COMPLETED ·Phase: PHASE2

Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload

NCT00379483 ·Status: COMPLETED ·Phase: PHASE2

Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)

NCT00171301 ·Status: COMPLETED ·Phase: PHASE4

Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload

NCT00564941 ·Status: COMPLETED ·Phase: PHASE4

Changes in Pituitary Iron and Volume With Deferasirox

NCT01376622 ·Status: COMPLETED

A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.

NCT00390858 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study

NCT00873041 ·Status: COMPLETED ·Phase: PHASE2

Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload

NCT00600938 ·Status: COMPLETED ·Phase: PHASE2

Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox

NCT01394029 ·Status: COMPLETED

Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients

NCT00529152 ·Status: COMPLETED ·Phase: PHASE3

Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients

NCT00349453 ·Status: COMPLETED ·Phase: PHASE2

Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients

NCT00303329 ·Status: COMPLETED ·Phase: PHASE2

Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients

NCT01825512 ·Status: COMPLETED ·Phase: PHASE3

Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias

NCT00061763 ·Status: COMPLETED ·Phase: PHASE2

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

NCT00110617 ·Status: COMPLETED ·Phase: PHASE2

Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses

NCT01948817 ·Status: WITHDRAWN ·Phase: PHASE2

Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

NCT02943668 ·Status: TERMINATED ·Phase: PHASE2

Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)

NCT03203850 ·Status: TERMINATED ·Phase: PHASE2

Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)

NCT02125877 ·Status: COMPLETED ·Phase: PHASE2

Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations

NCT01911871 ·Status: COMPLETED

Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).

NCT01090323 ·Status: COMPLETED ·Phase: PHASE2

Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis

NCT00000595 ·Status: COMPLETED ·Phase: PHASE2

A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer

NCT02905539 ·Status: COMPLETED ·Phase: PHASE4